Literature DB >> 20890242

Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Joo Young Shin1, Se Joon Woo, Hyeong Gon Yu, Kyu Hyung Park.   

Abstract

PURPOSE: To compare the efficacy and safety of half-fluence photodynamic therapy (PDT) and conventional PDT in chronic central serous chorioretinopathy.
METHODS: A multicenter retrospective comparison study. Retrospective review of 60 patients including 29 patients (34 eyes) who received half-fluence PDT and 31 patients (33 eyes) who received conventional PDT for the treatment of chronic central serous chorioretinopathy. Best-corrected visual acuity, central fovea retinal thickness and resolution of subretinal fluid on optical coherence tomography, and choroidal perfusion decrease on indocyanine green angiography were assessed. Choriocapillaris perfusion decrease was quantified as mean gray value ratio of treated and nontreated areas using commercial imaging software.
RESULTS: Treatment success without recurrence was achieved in 32 of 34 eyes (94.1%) treated with half-fluence PDT and 33 of 33 eyes (100%) treated with conventional PDT (P = 0.493). There was no difference in final best-corrected visual acuity (logarithm of the minimal angle of resolution) between the 2 groups (0.17 ± 0.32 vs. 0.21 ± 0.39; P = 0.603). Choriocapillaris perfusion decrease quantified from post-PDT indocyanine green angiography was significantly more severe in the conventional PDT group (P = 0.006), and it showed a positive correlation with retinal thinning after PDT (R = 0.380; P < 0.001).
CONCLUSION: Half-fluence PDT is as effective as conventional PDT, while minimizing the deleterious effect on choriocapillaris perfusion and retinal thickness.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20890242     DOI: 10.1097/IAE.0b013e3181e378f2

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  43 in total

1.  Combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-06       Impact factor: 3.117

2.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

3.  Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

Authors:  Serra Arf; Mumin Hocaoglu; Isil Sayman Muslubas; Murat Karacorlu
Journal:  Int Ophthalmol       Date:  2016-07-08       Impact factor: 2.031

4.  Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Authors:  Andrea Russo; Raffaele Turano; Francesco Morescalchi; Elena Gambicorti; Anna Cancarini; Sarah Duse; Ciro Costagliola; Francesco Semeraro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-10       Impact factor: 3.117

Review 5.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

6.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

7.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

8.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

9.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

Review 10.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.